

FEDERAL REPUBLIC
OF GERMANY



GERMAN
PATENT AND
TRADEMARK OFFICE

(12) [German] Translation of the
European Patent
(97) EP 0 808 162 B 1
(10) DE 696 02 424 T 2

(51) International Patent Clas-
sification:
A 61 K 31/40

DE 696 02 424 T 2

(21) German File Number: 696 02 424.1
(86) PCT File Number: PCT/EP96/00498
(96) European File Number: 96 902 984.2
(87) PCT Publication Number: WO 96/24348
(86) Date of PCT Application: February 7, 1996
(87) Date of Publication of
the PCT application: August 15, 1996
(97) First publication by the EPO: November 26, 1997
(97) Date of publication of the
the grant of patent at the EPO: May 12, 1999
(47) Date of publication in the
Official Gazette: October 7, 1999

(30) Convention Priority:
19503995 February 8, 1995 DE
483635 June 7, 1995 US
(73) Patentee:
Boehringer Mannheim Pharmaceuticals
Corp.-Smithkline Beecham Corp. Ltd. Partnership
No. 1, Gaithersburg, MD, US
(74) Agent:
No agent is appointed at this time
(84) Designated States:
AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL,
PT, SE

(72) Inventor(s):
LUKAS-LASKEY, Mary Ann, Rosemont, PA 19010,
US; RUFFOLO, Robert, Jr., Spring City, PA 19075,
US; SHUSTERMAN, Neil, Wynnewood, PA 19096,
US; SPONER, Gisbert, D-69514 Laudenbach, Ger-
many; STREIN, Klaus, D-69503 Hemsbach, Germany

(34) USE OF CARBAZOLE COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF
CONGESTIVE HEART FAILURE

Note: Anyone may oppose, within nine months of publication of the indication to the grant
of the European patent, the granted European patent at the European Patent Office. The
opposition must be made in writing and with reasons stated. The opposition is only con-
sidered as having been made when the opposition fee has been paid (European Patent
Agreement Art. 99 (1)).

The translation was submitted by the patentee in accordance with IntPatUG 1991 Art. II § 3
para. 1. Its content has not been checked by the German Patent and Trademark Office.

DE 696 02 424 T 2

29.05.99

European Patent Application No.: 96 902 984.2

Field of the Invention

The present invention relates to a new method of treatment using compounds which are dual non-selective β -adrenoceptor and α_1 -adrenoceptor antagonists. In particular the carbazol-4-yloxypropanolamine compounds of Formula 1, preferably carvedilol, for decreasing the mortality of patients suffering from congestive heart failure (CHF). The invention also relates to a method of treatment using compounds which are dual nonselective β -adrenoceptor and α_1 -adrenoceptor antagonists in particular the carbazol-4-yloxypropanolamine compounds of Formula I, preferably carvedilol, in conjunction with one or more other therapeutic agents. Said agents being selected from the group consisting of angiotensin converting enzyme (ACE) inhibitors, diuretics, and cardiac glycosides, for decreasing the mortality of patients suffering from CHF. The invention further relates to an incremental application scheme for administering compounds which are β -adrenoceptor and α_1 -adrenoceptor antagonists.

Background of the Invention

Congestive heart failure occurs as a result of impaired pumping capability of the heart and is associated with abnormal retention of water and sodium. Traditionally, treatment of chronic mild failure has included limitation of physical activity, restriction of salt intake, and the use of a diuretic. If these measures are not sufficient, a cardiac glycoside, which is an agent that increases the force

29-05-98

- 2 -

of myocardial contraction, is typically added to the treatment regimen.

Subsequently, angiotensin converting enzyme inhibitors, which are compounds that prevent the conversion of angiotensin I into the pressor-active angiotensin II, are prescribed for chronic treatment of congestive heart failure, in conjunction with a diuretic, a cardiac glycoside, or both.

Also, congestive heart failure is a well-known cardiac disorder which results in an excess mortality; Applefeld, M.M., (1986) Am. J. Med., 80 Suppl. 2B, 73-77. Therefore, therapeutic agents that would decrease the mortality resulting from CHF in patients suffering from CHF are highly desirable.

J. Cardiovasc. Pharmacol. 1992, 19, Suppl. 1 PS62-7, Das Gupta P. et al.: "Can intravenous beta-blockade predict long-term hemodynamic benefit in chronic congestive heart failure secondary to ischemic heart disease? A comparison with oral carvedilol." relates to initial studies with carvedilol and indicates some positive effects with regards to hemodynamics and symptoms.

J. Cardiovasc. Pharmacol. 1992, 19, Suppl. 1 PS117-21, Senior R. et al.: "Effects of carvedilol on ventricular arrhythmias" relates to the beneficial effect of carvedilol on the left ventricular function in a group of patients suffering from CHF and exclusively discusses the effect of carvedilol on arrhythmias in various cardiovascular function disorders.

Summary of the Invention


29-05-99

- 3 -

The present invention provides a new use of compounds which are dual non-selective β -adrenoceptor and α_1 -adrenoceptor antagonists for the preparation of medicaments for the treatment of congestive heart failure. In particular, the carbazol-4-yloxypropanolamine compounds of Formula I are preferred as therapeutics for decreasing mortality resulting from congestive heart failure in mammals, in particular, alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of ACE inhibitors, diuretics, and cardiac glycosides. The present invention preferably provides a method of treatment, alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of ACE inhibitors, diuretics, and cardiac glycosides, for the compound of Formula I wherein R_1 is -H, R_2 is -H, R_3 is -H, R_4 is -H, X is 0, Ar is phenyl, R_5 is ortho-OCH₃, and R_6 is -H, said compound being better known as carvedilol, which is (1-(carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy) ethyl]amino]2-propanol), or a pharmaceutically acceptable salt thereof.

Detailed Description of the Invention

U. S. Patent Number 4 503 067 discloses carbazol-(4)-yloxypropanolamine compounds of Formula I:



29-05-99

- 4 -

wherein

R_1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl,

R_2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl, and phenylpropyl,

R_3 is hydrogen or lower alkyl of up to 6 carbon atoms,

R_4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R_4 together with R_5 can represent $-\text{CH}_2-\text{O}-$,

X is a valency bond, $-\text{CH}_2$, oxygen or sulfur,

Ar is selected from phenyl, naphthyl, indanyl, and tetrahydronaphthyl,

R_5 and R_6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a $-\text{CONH}_2-$ group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkylsulphonyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms, or


R_5 and R_6 together represent methylenedioxy,

and pharmaceutically acceptable salts thereof.

This patent further discloses a compound of Formula I, better known as carvedilol, which is 1-(carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol having the structure shown in Formula II:

29-05-99

- 5 -



Formula I compounds, of which carvedilol is exemplary, are novel multiple action drugs useful in the treatment of mild to moderate hypertension. Carvedilol is known to be both a competitive non-selective β -adrenoceptor antagonist and a vasodilator, and is also a calcium channel antagonist at higher concentrations. The vasodilatory actions of carvedilol result primarily from an α_1 -adrenoceptor blockade, whereas the β -adrenoceptor blocking activity of the drug prevents reflex tachycardia when used in the treatment of hypertension. These multiple actions of carvedilol are responsible for the antihypertensive efficacy of the drug in animals, particularly in humans; See Willette, R.N., Sauermelch, C.F. and Ruffolo, R.R., Jr. (1990) Eur. J. Pharmacol., 176, 237-240; Nichols, A.J., Gellai, M. and Ruffolo, R.R., Jr. (1991) Fundam. Clin. Pharmacol., 5, 25-38; Ruffolo, R.R. Jr., Gellai, M., Hieble, J.P., Willette, R.N. and Nichols, A.J. (1990) Eur. J. Clin. Pharmacol., 38, S82-588; Ruffolo, R.R., Jr., Boyle, D.A., Venuti, R.P. and Lukas, M.A. (1991) Drugs of Today, 27, 465-492; and Yue, T.-L., Cheng, H., Lysko, P.G., McKenna, P.J., Feuerstein, R., Gu, I., Lysko, K.A., Davis, L.L. and Feuerstein, G. (1992) J. Pharmacol. Exp. Ther., 263, 92-98.

The antihypertensive action of carvedilol is mediated primarily by decreasing total peripheral vascular resistance without causing the concomitant reflex changes in heart rate commonly associated with other antihypertensive agents; Willette, R.N., et al. *supra*; Nichols, A.J., et al.

29-05-93

- 6 -

supra; Ruffolo, R.R., Jr., Gellai, M., Hieble, J.P., Willette, R.N. and Nichols, A.J. (1990) *Eur. J. Clin. Pharmacol.*, 38, S82-588. Carvedilol also markedly reduces infarct size in rat, canine, and porcine models of acute myocardial infarction; Ruffolo, R.R., Jr., et al., *Drugs of Today*, *supra*, possibly as a consequence of its antioxidant action in attenuating oxygen free radical-initiated lipid peroxidation; Yue, T.-L. et al. *supra*.

Recently, it has been discovered in clinical studies that pharmaceutical compounds which are dual non-selective β -adrenoceptor and α_1 -adrenoceptor antagonists, in particular the compounds of Formula I, preferably carvedilol, alone or in conjunction with conventional agents, said agents being ACE inhibitors, diuretics, and cardiac glycosides, are effective therapeutic agents for treating CHF. The use of agents, such as carvedilol in treating CHF is surprising, since, in general, β -blockers are contraindicated in patients suffering from heart failure, because β -blockers are known to have undesirable cardiodepressive effects. The most surprising observation from the studies in which the instant compounds were used to treat CHF is that said compounds, in particular carvedilol, are able to decrease the mortality resulting from CHF in humans by about 67%. Furthermore, this result is present across all classifications of CHF and both etiologies (ischemic and non-ischemic). This result is surprising since two recent mortality studies using the β -blockers metoprolol (Waagstein, et al., (1993) *Lancet*, 342, 1441-1446) and bisoprolol (CIBIS investigators and committees, (1994) 90, 1765-1773) in the treatment of CHF showed no difference in mortality between drug-treated patients and placebo-treated patients.

29-05-99

- 7 -

According to the method of treatment of the present invention, the desirable therapeutic effect of the compounds of Formula 1, particularly carvedilol, may be augmented by using any one of said compounds, or any pharmaceutically acceptable salt of said compounds, in conjunction with ACE inhibitors, diuretics, and cardiac glycosides, which are effective therapeutic agents for the treatment of CHF. In particular, the preferred ACE inhibitors of the present invention are selected from the group consisting of captopril, lisinopril, fosinopril, and enalapril, or any pharmaceutically acceptable salts thereof and the preferred diuretics of the present invention are hydrochlorothiazide, furosemide, or torasemide or any pharmaceutically acceptable salts thereof. The preferred cardiac glycosides of the present invention are digoxin, β -methyldigoxin or digitoxin. The desirable therapeutic benefits of the compounds of Formula I, particularly carvedilol, are additive with those of such ACE inhibitors, or diuretics, or cardiac glycosides when administered in combination therewith. Captopril is commercially available from E.R. Squibb & Sons, Inc. Lisinopril, enalapril, and hydrochlorothiazide are commercially available from Merck & Co. Furosemide is commercially available from Hoechst-Roussel Pharmaceuticals, Inc. Digoxin is commercially available from Burroughs Wellcome Co. and Boehringer Mannheim GmbH. Digitoxin, β -methyldigoxin, fosinopril and torasemide are commercially available from Boehringer Mannheim GmbH.

Compounds of Formula I may be conveniently prepared as described in U.S. Patent Number 4 503 067. Carvedilol is commercially available from SmithKline Beecham Corporation and Boehringer Mannheim GmbH (Germany).

29-05-93

- 8 -

Pharmaceutical compositions of the compounds of Formula I, including carvedilol, alone or in combination with ACE inhibitors, or diuretics, or cardiac glycosides may be administered to patients according to the present invention in any medically acceptable manner, preferably orally. For parenteral administration, the pharmaceutical composition will be in the form of a sterile injectable liquid stored in a suitable container such as an ampoule, or in the form of an aqueous or non-aqueous liquid suspension. The nature and composition of the pharmaceutical carrier, diluent, or excipient will, of course, depend on the intended route of administration, for example whether by intravenous or intramuscular injection.

Pharmaceutical compositions of the compounds of Formula I for use according to the present invention may be formulated as solutions or lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use. The liquid formulation is generally a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water, or buffered sodium or ammonium acetate solution. Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as ethanol, polyvinylpyrrolidone, gelatin, hydroxycellulose, acacia, polyethylene glycol, mannitol, sodium chloride, or sodium citrate.

Alternatively, these compounds may be encapsulated, tabbed, or prepared in an emulsion or syrup for oral administration. Pharmaceutically acceptable solid or liquid car-

28-08-99

- 9 -

riers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline, ethanol, and water. Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar, or gelatin. The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit. The pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing, and filling for hard gelatin capsule forms. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion, or an aqueous or non-aqueous suspension. Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.

Compounds having the above-mentioned dual properties are preferably administered following a three-stage application scheme. This scheme is characterized by the fact that incremental dosages of the active ingredient are administered to patients over a certain period of time, until the regular maintenance dosage is received. If this maintenance dosage is defined as the setting value being 100%, it was found that the application regimen in a first phase should extend for a period of 7 to 28 days, whereby only 10% to 30% of the setting dose are administered. Following this phase, a second application regimen should follow, wherein a dosage of 20% to 70% of the setting dose is administered to the patient for a period of 7 to 28 days. After termination of this phase, the third application period follows,

29-05-99

- 10 -

wherein the daily complete setting dose (maintenance dose) is administered. The daily maintenance dose can vary between 10 mg to 100 mg of said active ingredient.

In case of carvedilol, dosing in humans for the treatment of disease according to the present invention should not exceed a dosage range from about 3.125 mg to about 50 mg of the compounds of Formula I, particularly carvedilol, preferably given twice daily. As one of ordinary skill in the art will readily comprehend, the patient should be started on a low dosage regimen of the desired compound of Formula I, particularly carvedilol, and monitored for well-known symptoms of intolerance to such compound, e.g. fainting. Once the patient is found to tolerate such compound, the patient should be brought slowly and incrementally up to the maintenance dose. The preferred course of treatment is to start the patient on a dosage regimen with formulations which contain either 3.125 mg or 6.25 mg of active compound per single unit, preferably given twice daily, for 7 to 28 days. The choice of initial dosage most appropriate for the particular patient is determined by the practitioner using well-known medical principles, including, but not limited to, body weight. In the event that the patient exhibits medically acceptable tolerance of the compound for two weeks, the dosage is doubled at the end of the two weeks and the patient is maintained at the new, higher dosage for an additional period, preferably to two more weeks, and observed for signs of intolerance. This course is continued until the patient is brought to a maintenance dose. The preferred maintenance dose is 25.0 mg of active compound per single unit, preferably given twice daily, for patients having a body weight of up to 85 kg. For patients having a body weight of over 85 kg, the maintenance dose is between about 25.0 mg and about 50.0 mg, preferably given twice

29-05-99

- 11 -

daily, preferably about 50.0 mg of active compound per single unit, preferably given twice daily.

The present invention relates also to method of treatment for decreasing mortality resulting from congestive heart failure in mammals comprising internally administering to said mammal in need thereof an effective amount of carvedilol according to the following schedule:

- (a) a pharmaceutical formulation which contains either 3.125 mg or 6.25 mg carvedilol per single unit for a period of 7 to 28 days, given once or twice daily,
- (b) thereafter a pharmaceutical formulation which contains 12.5 mg carvedilol per single unit for a period of additional 7 to 28 days, given once or twice daily, and
- (c) finally a pharmaceutical formulation which contains either 25.0 mg or 50.0 mg carvedilol per single unit, given once or twice daily as a maintenance dose.

Dosing in humans for the treatment of disease according to the present invention includes the combination of compounds of Formula I with conventional agents. For example, the usual adult dosage of hydrochlorothiazide is 25 mg to 100 mg daily as a single dose or divided dose. The recommended starting dose for enalapril is 2.5 mg administered once or twice daily. The usual therapeutic dosing range for enalapril is 5 to 20 mg daily, given as a single dose or two divided doses. For most patients the usual initial daily dosage of captopril is 25 mg three times per day (t.i.d.), with most patients having a satisfactory clinical improvement at 50 mg or 100 mg three times per day (t.i.d.).

29-05-99

- 12 -

It will be appreciated that the actual preferred dosages of the compounds being used in the compositions of this invention will vary according to the particular composition formulated, the mode of administration, the particular site of administration, and the host being treated.

No unacceptable toxicological effects are expected when the compounds of Formula 1, including the compound of Formula II, are used according to the present invention. The example which follows is intended in no way to limit the scope of this invention, but is provided to illustrate how to use the compounds of this invention. Many other embodiments will be readily apparent to those skilled in the art.

Experimental Section

Mortality Studies in CHF Patients

Summary: To determine if β -adrenergic blockade might inhibit the deleterious effects of the sympathetic nervous system on survival in heart failure (CHF), 1,052 patients with CHF were prospectively enrolled into a multi-center trial program, in which patients were randomly assigned (double-blind) to between six and twelve months' treatment with placebo (PBO) or carvedilol (CRV). After a common screening period, patients with class II-IV CHF (see next paragraph for the definitions of the classification of CI) and an ejection fraction < 0.35 were assigned to one of four protocols based on performance on a six minute walk test. PBO or CRV was added to existing therapy with digoxin, diuretics, and an ACE inhibitor. All-cause mortality was monitored by a prospectively constituted Data and Safety Monitoring Board (DSMB). After 25 months of enrollment, the DSMB recommended termination of the program be-

cause of a favorable effect of CRV on survival. By intention-to-treat, mortality was 8.2% in the PBO group but only 2.9% in the CRV group ($P = 0.0001$, Cochran-Mantel-Haensel analysis). This represented a reduction in risk of death by CRV of 67% (95% CI: 42% to 81%). The treatment effect was similar in patients with class II and class III-IV symptoms. Mortality was reduced in class II patients from 5.9% to 1.9%, a 68% reduction (95% CI: 20% to 97%) [$P = 0.015$]), and in class III-IV patients from 11.0% to 4.2%, a 67% reduction (95% CI: 30% to 84%), [$P = 0.004$, log-rank]. Importantly, the effect of CRV was similar in ischemic heart disease (risk reduced by 67%, $P = 0.003$) and in non-ischemic dilated cardiomyopathy (risk reduced by 67%, $P = 0.014$). In conclusion, the addition of CRV to conventional therapy is associated with a substantial (67%) reduction in the mortality of patients with chronic CHF. The treatment effect is seen across a broad range of severity and etiology of disease.

As used herein, "Class II CHF" means patients with cardiac disease resulting in slight or moderate limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain. "Class III CHF" means patients with cardiac disease resulting in marked limitations of physical activity. They are comfortable at rest. Less than ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain. "Class IV CI" means patients with cardiac disease resulting in inability to carry out any physical activity without discomfort symptoms or cardiac insufficiency or anginal syndrome. "Less than ordinary physical activity" means climbing one flight of stairs, or walking one hundred meters.

29.05.98

- 14 -

Design of Study: Patients on background therapy with diuretics, ACE inhibitors and/or digoxin were stratified on the basis of baseline submaximal exercise performance, into one of four trials:

- Study 220; a dose response study in moderate (NYHA II-IV) CHF with exercise testing as a primary endpoint.
- Study 221; a dose titration study in moderate (NYHA II-IV) CI with exercise testing as a primary endpoint.
- Study 239; a dose titration study in severe (NYHA III-IV) CHF with quality of life as a primary endpoint.
- Study 240; a dose titration study in mild (NYHA II-III) CHF with progression of CHF as a primary endpoint.

Sixty-four centers in the United States participated in the trial program. All sites conducted protocols 239 and 240, while 33 performed protocol 220 and 31 performed protocol 221.

Although each trial had its own individual objectives, the overall program objective defined prospectively was evaluation of all-cause mortality. Based upon a projected enrollment of 1,100 patients, the program had 90% power to detect a 50% reduction in mortality (two-sided) between carvedilol and placebo, assuming a mortality rate in the placebo group of 12% over the duration of the trials ($\alpha = 0.05$).

Randomization was preceded by a screening and challenge period common to the four protocols. The purpose of the screening period was to qualify patients for study entry, obtain reproducible baseline measurements, and stratify pa-

tients into the appropriate trial based on submaximal exercise testing. During the challenge period, patients received low-dose open-label carvedilol (6.25 mg b.i.d.) for two weeks. Patients unable to tolerate this dose did not proceed to randomization. Patients tolerating low-dose carvedilol were then randomized to blinded medication (carvedilol or placebo) with the dose titrated over several weeks in the range of 6.25 mg to 50 mg b.i.d. (or equivalent level of placebo). The maintenance phase of each study ranged from six to twelve months, after which patients had the option of receiving open-label carvedilol in an extension study.

Results: The analysis presented below corresponds to the data set on which the DSMB made the recommendation to terminate the trials. Included in this intent-to-treat analysis are all patients enrolled in the US trials as of January 20, 1995; 624 receiving carvedilol and 356 placebo. An analysis of baseline patient characteristics (Table 1) shows good balance between the randomized groups.

Table 1: US Carvedilol Heart Failure Trials - Baseline Characteristics

Characteristics	Placebo (n = 356)	Carvedilol (n = 624)
Age mean + SD (years)	59.9 + 11.7	58.8 + 11.8
Sex (% men)	62%	62%
Etiology (% ischemic)	43%	40%
Severity of CHF		
Class II	41%	41%
Class III-IV	40%	39%
Unknown	19%	20%
LV ejection fraction, mean + SD	0.22 + 0.07	0.23 + 0.08
Six Minute walk (m + SD)	373 + 88	379 + 81
Blood pressure (mm Hg)	115/73	115/73
Heart rate (bpm + SD)	85 ± 13	86 ± 13

29-05-99

- 16 -

The overall mortality results for the program are shown in Table 2. All deaths that occurred during the intent-to-treat period are included. Treatment with carvedilol resulted in a 67% reduction in the risk of all-cause mortality. Analysis of mortality by certain baseline characteristics shows this to be a broad effect regardless of severity or etiology of CI. The effect was uniform in patients with mild heart failure or moderate to severe heart failure. Similarly, the mortality reduction was equivalent in patients with ischemic or non-ischemic heart failure.

Table 2: Evaluation of Mortality in US Carvedilol CHF Studies


	Carvedilol	Placebo	Risk Reduction (95% CI)	p Value*
All Cause Mortality	18/624 (2.9%)	29/356 (8.2%)	67% (42 to 81)	< 0.001
Class II CHF	7/361 (1.9%)	12/202 (5.9%)	68% (20 to 97)	0.015
Class III to IV CHF	11/263 (4.2%)	17/154 (11.0%)	66% (30 to 84)	0.004
Ischemic Etiology	10/311 (3.2%)	16/178 (8.9%)	67% (32 to 85)	0.003
Non-Ischemic Etiology	8/313 (2.5%)	13/178 (7.3%)	67% (20 to 86)	0.014

* Cochran-Mantel-Haensel Analysis

The preceding is illustrative of the use of the compounds of this invention.

C l a i m s

1. The use of a compound which is both a β -adrenoceptor antagonist and a α_1 -adrenoceptor antagonist for the manufacture of a medicament for decreasing mortality resulting from congestive heart failure in mammals, alone or in conjunction with one or more other therapeutic agents, said agents selected from the group consisting of an angiotensin converting enzyme inhibitor, a diuretic, and a cardiac glycoside.
2. The use of a compound according to Claim 1, wherein said compound is subject of Formula I:



wherein

R_1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl,

R_2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzoyl phenylethyl and phenylpropyl,

R_3 is hydrogen or lower alkyl of up to 6 carbon atoms,

29.05.99

- 2 -

R_4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R_4 together with R_5 can represent $-\text{CH}_2-\text{O}-$,

X is a valency bond, $-\text{CH}_2$, oxygen or sulfur,

Ar is selected from phenyl, naphthyl, indanyl and tetrahydronaphthyl,

R_5 and R_6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a $-\text{CONH}_2-$ group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkylsulphonyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms, or

R_5 and R_6 together represent methylenedioxy,

and pharmaceutically acceptable salts thereof.

3. The use of a compound according to Claims 1 or 2, wherein said compound is carvedilol.
4. The use of a compound according to Claim 3, whereby a pharmaceutical formulation containing either 3.125 mg or 6.25 mg carvedilol in a single unit are administered for a period of 7 to 28 days, once or twice daily as an initial dose.
5. The use of a compound according to Claim 3, whereby a pharmaceutical formulation containing 12.5 mg carvedilol in a single unit are administered for a period of 7 to 28 days, once or twice daily.
6. The use of a compound according to Claim 3, whereby a pharmaceutical formulation containing either 25.0 mg or 50.0 mg carvedilol in a single unit are administered once or twice as a maintenance dose.

29-06-99

- 3 -

7. The use of a compound according to Claim 1, wherein said ACE inhibitor is selected from the group consisting of captopril, lisinopril, fosinopril, or enalapril, or any pharmaceutically acceptable salt thereof.
8. The use of a compound according to Claim 1, wherein said diuretic is selected from the group consisting of hydrochlorothiazide, torasemide, or furosemide, or any pharmaceutically acceptable salt thereof.
9. The use of a compound according to Claim 1, wherein said cardiac glycoside is selected from the group consisting of digoxin, β -methyl-digoxin, or digitoxin.
10. The use of carvedilol for the manufacture of a medicament for decreasing mortality resulting from congestive heart failure in mammals according to the following regimen:
 - (a) administering a pharmaceutical formulation which contains either 3.125 mg or 6.25 mg carvedilol per single unit for a period of 7 to 28 days, given once or twice daily,
 - (b) administering thereafter a pharmaceutical formulation which contains 12.5 mg carvedilol per single unit for an additional period of 7 to 28 days, given once or twice daily, and
 - (c) administering finally a pharmaceutical formulation which contains either 25.0 mg or 50.0 mg carvedilol per single unit, given once or twice daily as a maintenance dose.
11. The use of carvedilol according to Claim 10, whereby carvedilol is administered in conjunction with one or more other therapeutic agents, said agents being se-

29-05-98

- 4 -

lected from the group consisting of an angiotensin converting enzyme inhibitor, a diuretic, and a cardiac glycoside.

12. Use of a compound according to Claim 1 for the preparation of a medicament for the treatment of CHF to be administered in a daily maintenance dose of 10 mg to 100 mg, said medicament being administered in incremental dosage schemes comprising three dose regimens, the first regimen comprising administering an amount of 10% to 30% of the daily maintenance dose of the compound for a period of 7 to 28 days, the second regimen comprising administering an amount of 20% to 70% of said daily dose for a period of 7 to 28 days and a third regimen comprising administering 100% of said daily dose starting after termination of the second regimen.